Ten-year surveillance of antimicrobial resistance of Streptococcus pneumoniae in a south-west German teaching hospital  by Abb, Jochen
International Journal of Infectious Diseases (2005) 9, 60—61http://intl.elsevierhealth.com/journals/ijidLETTER TO THE EDITORTen-year surveillance of antimicrobial resistance
of Streptococcus pneumoniae in a south-west
German teaching hospital
Pneumococcal resistance has shown a steady
increase worldwide over recent decades.1 Penicil-
lin-resistant pneumococci were first reported in
Australia in 1967 and then became widespread dur-
ing the 1980s and 1990s. Pneumococcal strains with
resistance to erythromycin, tetracycline, and cotri-
moxazole were also identified in the late 1960s and
early 1970s.1 More recently, pneumococci resistant
to extended-spectrum cephalosporins and fluoroqui-
nolones have been reported in the United States,
South Africa and Europe.2 The rapid development of
pneumococcal resistance to a broad range of anti-
microbial agents has implications for the treatment
of patients with systemic infections. To establish a
rational basis for the therapy of pneumococcal infec-
tions, a prospective ten-year surveillance study of
pneumococcal resistance in a 1070-bed south-west
German teaching hospital was performed.
In vitro activity of penicillin G, ceftriaxone, ery-
thromycin and rifampin were studied against 988
non-repeat clinical isolates of Streptococcus pneu-
moniae. Minimum inhibitory concentrations (MICs)
were determined by the E test (AB Biodisk, Solna,
Sweden), which has proved to be a reliable alter-
native to conventional methods for antimicrobial
susceptibility testing of pneumococci.3 The 988 pri-
mary clinical isolates of S. pneumoniae were col-
lected from hospitalized patients between October
1992 and February 2003. Of the pneumococcal iso-
lates, 765 were from adults and 223 from children.
Sources of isolation of the strains were: lower









Penicillin G <0.016—1.5 0.016 0.032
Ceftriaxone <0.016—1.5 <0.016 0.032
Erythromycin 0.016—>256 0.125 1.5
Rifampin <0.016—2.0 0.032 0.064
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doi:10.1016/j.ijid.2004.06.007(44), cerebrospinal fluid (47), wounds (30) and peri-
toneum (22). Streptococcus pneumoniae ATCC
33400 was employed as a control strain. MIC values
were converted to categories of susceptibility by
using the NCCLS standard M 100 - S 12.4
Table 1 summarizes the data on MIC determina-
tions in pneumococcal strains. Forty-nine of the 988
isolates (5.0%) showed intermediate and two isolates
(0,2%) showed high level resistance to penicillin.
Three of the 988 strains (0.3%) demonstrated inter-
mediate resistance and only one isolate (0.1%)
showed high-level resistance to ceftriaxone. Ten
of the 988 pneumococcal isolates (1.0%) were inter-
mediately resistant and 104 isolates (10.5%) highly
resistant to erythromycin.Only twoof the988 strains
(0.2%) demonstrated intermediate resistance to
rifampin and isolates with high-level resistance to
rifampin were not observed. Resistance rates to
penicillin remained remarkably constant (ranging
from 5.0% to 7.8% per year) over the ten-year sur-
veillance period. Resistance rates to erythromycin,
however, showed a more than threefold increase
from 6.0% during 1993 to 18.8% during 2002.
Compared to those regions of the world with a
high prevalence of pneumococcal resistance to anti-
microbial agents,1 the situation in Germany remains
favourable. Previous studies have shown that the
rate of pneumococcal isolates with a reduced sus-
ceptibility to penicillin (MIC >0.1 mg/L) ranged
from 1% to 7%.5—7 The occurrence of strains with
high-level resistance to penicillin (MIC>1.0 mg/L) is
extremely rare.5—7 High-level resistance to erythro-
mycin, however, has shown a constant rise to rates
of more than 15% over the last decade.6,7
Thus the current recommendation for the use








937 (94.8) 49 (5.0) 2 (0.2)
984 (99.6) 3 (0.3) 1 (0.1)
874 (88.5) 10 (1.0) 104 (10.5)
986 (99.8) 2 (0.2) 0
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Letter to the Editor 61of patients with community-acquired pneumonia or
other clinical manifestations of pneumococcal
infections should be carefully monitored. Alterna-
tive agents, such as the newer quinolones, have
shown promising results in previous studies and
should be further evaluated.8,9 The data presented
underline the need for the continuous surveillance
of antimicrobial susceptibility of S. pneumoniae as a
guide to appropriate treatment of patients with
pneumococcal infections.
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